Coherus exits TIGIT deal with Junshi, three months after Surface Oncology buyout
Coherus BioSciences is walking away from a three-year TIGIT pact with Shanghai Junshi Biosciences, several months after it acquired Surface Oncology and its TIGIT drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.